Guardian Pharmacy Operating Income Over Time
| GRDN Stock | 33.54 0.50 1.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Guardian Pharmacy Performance and Guardian Pharmacy Correlation. Will Consumer Staples Distribution & Retail sector continue expanding? Could Guardian diversify its offerings? Factors like these will boost the valuation of Guardian Pharmacy. Market participants price Guardian higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Guardian Pharmacy data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 0.2 | Return On Assets | Return On Equity |
Understanding Guardian Pharmacy requires distinguishing between market price and book value, where the latter reflects Guardian's accounting equity. The concept of intrinsic value - what Guardian Pharmacy's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Guardian Pharmacy's price substantially above or below its fundamental value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Guardian Pharmacy's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Guardian Pharmacy and related stocks such as 10X Genomics, Procept Biorobotics Corp, and Twist Bioscience Corp Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TXG | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (110.8 M) | (29.1 M) | (85.3 M) | (52.9 M) | (167.9 M) | (265.3 M) | (194.6 M) | (110.9 M) | (116.4 M) |
| PRCT | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (43.5 M) | (47.8 M) | (54.2 M) | (80.7 M) | (109.2 M) | (96.6 M) | (87 M) | (91.3 M) |
| TWST | (43.7 M) | (43.7 M) | (43.7 M) | (43.7 M) | (43.7 M) | (43.7 M) | (58.5 M) | (70.6 M) | (108.8 M) | (140.1 M) | (152.7 M) | (249 M) | (217.2 M) | (220.8 M) | (136.3 M) | (122.6 M) | (128.8 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (32.1 M) | (43.6 M) | (93.3 M) | (119.7 M) | (99.8 M) | (592.6 M) | (533.4 M) | (506.7 M) |
| NHC | 30.9 M | 78.9 M | 68.2 M | 72.1 M | 68 M | 67.1 M | 60.5 M | 54.1 M | 56.1 M | 49 M | 48.2 M | 50.9 M | 31.9 M | 57.1 M | 85.8 M | 98.6 M | 51.7 M |
| QDEL | (100 K) | 13.7 M | 8.8 M | 4.2 M | (9.2 M) | 2.7 M | (4.4 M) | 9.6 M | 95.9 M | 92.7 M | 1.1 B | 906 M | 843.7 M | 139.1 M | (2 B) | (919.2 M) | (873.2 M) |
| MD | 9.1 M | 355.4 M | 389.5 M | 452.1 M | 513 M | 557.9 M | 571.7 M | 480.1 M | 445.8 M | 171.8 M | 98.1 M | 202.9 M | 172.7 M | 7.3 M | (68.7 M) | 231.1 M | 228.5 M |
| MESO | (986.5 K) | (48.7 M) | (60.1 M) | (72.4 M) | (113.4 M) | (55.9 M) | (90 M) | (77.3 M) | (80.2 M) | (74.9 M) | (109.1 M) | (80.6 M) | (69.3 M) | (84.1 M) | (62.4 M) | (56.2 M) | (59 M) |
| JANX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (4.8 M) | (32.9 M) | (67.1 M) | (73 M) | (98.8 M) | (89 M) | (84.5 M) |
| EWTX | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (17.2 M) | (43.2 M) | (22.1 M) | (114.4 M) | (158.8 M) | (142.9 M) | (135.8 M) |
Guardian Pharmacy and related stocks such as 10X Genomics, Procept Biorobotics Corp, and Twist Bioscience Corp Operating Income description
Operating Income is the amount of profit realized from Guardian Pharmacy operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Guardian Pharmacy Services is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Guardian Pharmacy Services | GRDN |
Specialization | Consumer Staples, Consumer Staples Distribution & Retail |
| Business Address | 300 Galleria Parkway |
| Exchange | New York Stock Exchange |
null 33.54
Check out Guardian Pharmacy Performance and Guardian Pharmacy Correlation. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Guardian Pharmacy technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.